Spots Global Cancer Trial Database for esr1 mutation
Every month we try and update this database with for esr1 mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | NCT06065748 | Estrogen Recept... | Giredestrant Fulvestrant Abemaciclib Palbociclib Ribociclib LHRH Agonist FoundationOne L... | 18 Years - | Hoffmann-La Roche | |
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib | NCT02913430 | Metastatic Brea... | Fulvestrant Tamoxifen Palbociclib | 18 Years - | University of Pittsburgh |